| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/29/2009 | US7595343 Inhibitors of histone deacetylase |
| 09/29/2009 | US7595342 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions |
| 09/29/2009 | US7595341 Analogues of lipid mediators derived from ω-3 PUFAs and methods of use |
| 09/29/2009 | US7595340 Serotonin and norepinephrine reuptake inhibitor and uses thereof |
| 09/29/2009 | US7595339 Such as N-(4-Fluoro-benzyl)-4-(3-phenyl-indole-1-sulfonyl)-benzamide; Cannabinoid-1 (CB1) receptor; dietetics |
| 09/29/2009 | US7595338 Nitrilizing fluoroarene in presence of sodium hexamethyldisilazide or isopropyl magnesium halide, amidation, cyclization |
| 09/29/2009 | US7595337 Mitotic kinesin inhibitors |
| 09/29/2009 | US7595336 Isatine derivatives with neurotrophic activity |
| 09/29/2009 | US7595335 Containing microcrystalline cellulose, lubricant, colloidal silica and lactose; use in treating depression, Parkinson's disease and severe psychotic disorders, such as schizophrenia and schizoaffective disorders. |
| 09/29/2009 | US7595334 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
| 09/29/2009 | US7595333 Agent for improving acidosis |
| 09/29/2009 | US7595332 Such as N-(4-tert-butylphenyl)-4-(2-pyridinyl)benzamide for treatment of urinary incontinence, pain, inflammatory thermal hyperalgesia, and/or bladder overactivity |
| 09/29/2009 | US7595331 N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith |
| 09/29/2009 | US7595330 Such as 5-{6-[(Methylsulfonyl)methyl]-1H-benzimidazol-1-yl}-3-({(1R)-1-[2-(trifluoromethyl)phenyl]-ethyl}oxy)-2-thiophenecarboxamide; for conditions associated with polo-like kinases |
| 09/29/2009 | US7595329 4-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid; serotonin receptor agonist; gastroesophageal reflux disease, analgesic, cognition activator; less toxicity, good absorption, and metabolic stability |
| 09/29/2009 | US7595328 Administering gemifloxacin against antibiotic resistant bacteria |
| 09/29/2009 | US7595327 Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis |
| 09/29/2009 | US7595326 1-[4-(5-Bromopyrimidin-2-ylsulfanyl)phenyl]-3-(2-nitrobenzoyl)-urea; antiproliferative, water soluble compound with high bioavailability |
| 09/29/2009 | US7595325 1-[5-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-pyridin-3-yl]-3-(2-fluoro-5-methyl-phenyl)-urea; cancer |
| 09/29/2009 | US7595324 Substituted thieno[3,2-D]pyrimidines as HIV inhibitors |
| 09/29/2009 | US7595323 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
| 09/29/2009 | US7595322 Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester |
| 09/29/2009 | US7595321 Useful for the prevention and/or treatment of cognitive disorders; 3-Amino-N-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide, for example |
| 09/29/2009 | US7595320 Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof |
| 09/29/2009 | US7595319 Compounds having selective inhibiting effect at GSK3 |
| 09/29/2009 | US7595318 Conjugates which bind VLA-4; may also inhibit leukocyte adhesion; useful in the treatment of inflammatory diseases in a mammalian patient, such as asthma, Alzheimer's disease, atherosclerosis, AIDS, dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis |
| 09/29/2009 | US7595317 Antiarthritic agents; rheumatoid and osteoarthritis; corneal, epidermal, or gastric ulceration; tumor metastasis or invasion; periodontal disease; and bone disease; 4-[(2-methyl-4-quinolinyl)methoxy]-N-(1,3,5-trioxo-2,4-diazaspiro[5.5]undec-7-yl)benzamide trifluoroacetate, for example |
| 09/29/2009 | US7595316 2-(1-Cyclopentylpiperidin-4-yloxy)-5-(4-cyanophenyl)pyrimidine, for example; exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful for the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep disorders |
| 09/29/2009 | US7595315 Morpholine derivatives as norepinephrine reuptake inhibitors |
| 09/29/2009 | US7595314 Such as (2-morpholin-4-yl-5-nitro-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-methanone; for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease |
| 09/29/2009 | US7595313 Nitric oxide donating diuretic compounds, compositions and methods of use |
| 09/29/2009 | US7595312 (1) (S)-2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butan-1,4-dione, for example; treatment of headaches, particularly migraine or cluster headaches |
| 09/29/2009 | US7595311 Azepinoindole derivatives as pharmaceutical agents |
| 09/29/2009 | US7595310 Glucuronate salt of a piperazine compound |
| 09/29/2009 | US7595309 For therapy of bacterial infections and neoplasms, |
| 09/29/2009 | US7595307 Polysaccharide derivatives and uses in induction of an immune response |
| 09/29/2009 | US7595305 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 09/29/2009 | US7595304 Polymeric oligonucleotide prodrugs |
| 09/29/2009 | US7595302 for interfering with the DNA repair of double strand breaks (DSB); novel double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways |
| 09/29/2009 | US7595301 Staple type oligonucleotide and drug comprising the same |
| 09/29/2009 | US7595300 6-O-(1-(7-quinolyl)-3-propenyl)-11-amino-11-deoxy-3-(decladinosyl)-15-fluoroerythromycin 11,12-cyclic carbamate 2'-O-benzoate derivatives; pulmonary infections such as pneumonia, bronchitis, tonsillitis, and pharyngitis; skin disorders, acne; Streptococcus, Hemophilus |
| 09/29/2009 | US7595299 Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 09/29/2009 | US7595156 Genes for synthesis of FR-008 polyketides |
| 09/29/2009 | US7595067 Composition and method to augment and sustain neurotransmitter production |
| 09/29/2009 | US7595064 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| 09/29/2009 | US7595063 Compressed tablet formulation |
| 09/29/2009 | US7595055 Pharmaceutical composition comprising an extract or compounds isolated from Elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications |
| 09/29/2009 | US7595048 Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| 09/29/2009 | CA2562672C 4-cyano-phenoxy derivatives as androgen modulators |
| 09/29/2009 | CA2561839C Multi-phase contraceptive preparation based on a natural estrogen |
| 09/29/2009 | CA2550372C Alpha-hydroxy amides as bradykinin antagonists or inverse agonists |
| 09/29/2009 | CA2521391C Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
| 09/29/2009 | CA2498457C Composition for treating hemorrhoids |
| 09/29/2009 | CA2494601C N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| 09/29/2009 | CA2493370C Crystal forms of olanzapine and processes for their preparation |
| 09/29/2009 | CA2484460C Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-yl]-1-piperidinyl]ethyl]-.alpha..alpha. dimethyl-benzeneacetic acid |
| 09/29/2009 | CA2481263C Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system |
| 09/29/2009 | CA2469882C Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same |
| 09/29/2009 | CA2469350C 3-{4-methyl-3[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt |
| 09/29/2009 | CA2464042C Mptp affinity labels |
| 09/29/2009 | CA2457944C Polycyclic guanine phosphodiesterase v inhibitors |
| 09/29/2009 | CA2452036C 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity |
| 09/29/2009 | CA2438891C Method for preparing optically active dihydropyrones |
| 09/29/2009 | CA2434009C Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| 09/29/2009 | CA2427812C Novel .beta.-lactam compounds and process for producing the same |
| 09/29/2009 | CA2415354C Phospholipid derivatives of valproic acid and mixtures thereof |
| 09/29/2009 | CA2414586C Agent for therapeutic treatment of optic nerve diseases and the like |
| 09/29/2009 | CA2403232C 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds |
| 09/29/2009 | CA2399901C Weight-specific elixir dosage calculation reference |
| 09/29/2009 | CA2394079C Weight promoting composition, method and product |
| 09/29/2009 | CA2391085C Bis-basic compounds as tryptase inhibitors, processes for preparing them and their use as phamaceutical compositions |
| 09/29/2009 | CA2390295C A method for chemoprevention of prostate cancer |
| 09/29/2009 | CA2383983C Substituted indolealkanoic acids |
| 09/29/2009 | CA2379560C Purine derivatives inhibitors of tyrosine protein kinase syk |
| 09/29/2009 | CA2376367C Liquid composition for topical application |
| 09/29/2009 | CA2375670C 5-phenyl-pyrimidine derivatives |
| 09/29/2009 | CA2371853C Heterocyclic benzenesulphonamide compounds as bradykinin antagonists |
| 09/29/2009 | CA2354621C Transparent transdermal nicotine delivery devices |
| 09/29/2009 | CA2353962C Selective 5-ht6 receptor ligands |
| 09/29/2009 | CA2349330C Nitrogen containing heterobicycles as factor xa inhibitors |
| 09/29/2009 | CA2348391C Chromenone and chromanone derivatives as integrin inhibitors |
| 09/29/2009 | CA2347105C Controlled-release pharmaceutical composition with gastric residence |
| 09/29/2009 | CA2346862C Anionic-cationic polyion complexes comprising zwitterionic monomer component |
| 09/29/2009 | CA2338252C Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin |
| 09/29/2009 | CA2334923C Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
| 09/29/2009 | CA2328280C Thienopyrimidines |
| 09/29/2009 | CA2319798C Agent for preventing and curing hindrance of ischemic reperfusion |
| 09/29/2009 | CA2318208C Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 09/29/2009 | CA2315647C Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas |
| 09/29/2009 | CA2313372C Composition and method for prolonging the useful life of enteral feeding tubes |
| 09/29/2009 | CA2311922C Thienopyrimidines |
| 09/29/2009 | CA2310850C A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
| 09/29/2009 | CA2310661C Ep2-receptor agonists as neuroprotective agents for the eye |
| 09/29/2009 | CA2306573C Process for preparing antiosteoporotic agents |
| 09/29/2009 | CA2294812C Solid pharmaceutical composition containing benzofurane derivatives |
| 09/29/2009 | CA2293489C Inhibitors of dna immunostimulatory sequence activity |
| 09/29/2009 | CA2293433C Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors |
| 09/29/2009 | CA2289531C Composition and methods for treating alzheimer's disease and other amyloidoses |
| 09/29/2009 | CA2274758C Stable glassy state powder formulations |
| 09/29/2009 | CA2273852C Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |